Juan José Lozano

This study shows ZEB1 in cancer-associated fibroblasts regulates BCL2 to promote chemoresistance in cholangiocarcinoma, suggesting BCL2 inhibitors could enhance gemcitabine and cisplatin efficacy.

This study shows that combining Palbociclib with Telaglenestat prevents acquired resistance in colorectal cancer cells by counteracting metabolic reprogramming.

This study develops patient-derived liver biopsy organoids to model alcohol-associated liver disease and identifies disease-specific features and therapeutic responses.

This study maps the differentiation trajectory of iPSCs to hepatic stellate cells, identifying RORA as a key regulator of metabolic reprogramming and fibrosis.

This study identifies mitochondrial and metabolic reprogramming induced by SARS-CoV-2 accessory proteins in lung cells, revealing potential therapeutic targets.

The paper identifies copy-number intratumor heterogeneity as a predictor of relapse in stage II colon cancer, improving risk prediction beyond clinicopathological markers.

CNApp quantifies genomic copy number alterations in cancer and integrates them with clinical and molecular data to identify clinical implications.